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Introduction
HIV/AIDS statistics and models have been a source of much
controversy in South Africa. Until recently, most HIV/AIDS
models produced single estimates of the expected impact of the
epidemic, with no indication being given of the uncertainty
around these projections. The conclusions of different agencies
have differed substantially, with estimates of the number of HIV
infections in South Africa in 2005 ranging between 4.5 million1
and 6.3 million.2 The lack of uncertainty analysis has made the
estimates of the different agencies difficult to reconcile, which in
turn has undermined the credibility of HIV/AIDS models. The
lack of uncertainty analysis has also made it difficult for policy
makers to anticipate the range of possible HIV/AIDS scenarios
that might be expected in future.
Techniques developed to date to assess uncertainty in
HIV/AIDS projection models can be divided into two classes:
those appropriate to models that are calibrated against HIV
prevalence data, and those appropriate to models that are not
calibrated against empirical data. Examples of the latter include
Latin hypercube sampling,3,4 Monte Carlo simulation5,6 and
factorial sampling.7 Examples of the former are bootstrap methods
in conjunction with a least squares approach,8 and deriving
prediction intervals from maximum likelihood estimates.9 These
techniques developed for calibrated HIV/AIDS models can be
considered frequentist statistical methods, since they do not
make use of prior knowledge regarding the parameters being
estimated.10 Bayesian methods, which allow explicitly for such
prior knowledge, have been used to a very limited extent in
HIV/AIDS projection models.11–13
The objective of this paper is to estimate ranges of uncertainty
around key HIV/AIDS statistics in South Africa, using a Bayesian
approach. This approach acknowledges uncertainty with respect
to the principal epidemiological parameters, and integrates data
from four South African data sets into a single statistical frame-
work. The statistical framework is developed using the
ASSA2002 AIDS and Demographic model†, a deterministic
model of the HIV/AIDS epidemic in South Africa.14 This makes it
possible to derive 95% prediction intervals around the model
outputs and to obtain credibility intervals for the key epidemio-
logical parameters in the model. Although the approach is
described in relation to the ASSA2002 model, it could also be
applied to other calibrated HIV/AIDS models.
Method
The ASSA2002 AIDS and Demographic model is a combined
cohort component projection and HIV/AIDS model, developed
by the Actuarial Society of South Africa (ASSA) to simulate
the HIV/AIDS epidemic in South Africa. The model has been
described previously14 and is freely available online.15 The
model, which was originally programmed in Excel and Visual
Basic for Applications, was reprogrammed in C++ for the
purpose of this analysis. Uncertainty is considered in relation to
24 of the model parameters. These parameters fall into four
classes: parameters that determine patterns of sexual behaviour
and sexual mixing; parameters determining probabilities of HIV
transmission; parameters determining HIV survival in the absence
of antiretroviral treatment; and parameters determining the
extent of the bias in the data to which the model is calibrated.
Prior distributions, representing ranges of uncertainty around
these parameters, were specified for each of the 24 parameters,
based on a review of the literature. A brief description of these
parameters and the ASSA2002 model is provided in the supple-
mentary material online. A more detailed explanation of the
parameters and the literature on which the prior distributions
were based is given in a working paper.16
Four data sets were used in the calibration of the ASSA2002
model. The characteristics of these four data sets are summarized
in Table 1. For all four data sets, results are available separately
for each sex and each five-year age band. Six sources of bias in
these data were considered in the uncertainty analysis: incom-
pleteness of vital registration (under-reporting of deaths); bias
towards urban clinics in the early antenatal clinic surveys; exclu-
sion of women attending private health facilities in the antenatal
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HIV/AIDS statistics have been the source of much controversy
in South Africa, but often the extent of uncertainty around these
estimates is ignored. There is need for an assessment of the range
of uncertainty around often-quoted HIV/AIDS statistics. This analysis
determines ranges of uncertainty around the inputs and outputs of
the ASSA2002 AIDS and Demographic model of the South African
HIV/AIDS epidemic, using a generalized likelihood uncertainty
estimation approach. A sample of 500 parameter combinations was
drawn by weighting randomly generated parameter combinations
by likelihood functions defined on the basis of four South African
HIV/AIDS data sets. The estimated number of HIV infections in
mid-2005 was 5.1 million (95% prediction interval: 4.2–6.0 million),
equivalent to an HIV prevalence rate of 11.1% (9.1–13.1%). Between
mid-2004 and mid-2005, the estimated number of new HIV infections
was 490 000 (370 000–590 000) and the estimated number of AIDS
deaths was 320 000 (270 000–380 000). The posterior mean HIV
survival time was estimated to be 11.5 years (95% credibility
interval: 10.0–12.9 years), longer than estimated for elsewhere in
the developing world. This analysis confirms that South Africa is
experiencing a severe HIV/AIDS epidemic, and suggests that
HIV/AIDS epidemiology in the country probably differs from that
elsewhere in Africa.
†Although the ASSA2002 model is not the most recent version of the ASSA AIDS and
Demographic models, it does not differ significantly from the more recent ASSA2003
version of the model.
surveys; false positive reactions on the blood-based ELISA tests
used in the antenatal surveys; false positive reactions on the
saliva-based ELISA tests used in the household surveys; and bias
in antenatal surveys due to the effect of HIV on fertility.
The uncertainty analysis of the ASSA2002 model was con-
ducted using an approach based on the generalized likelihood
uncertainty estimation (GLUE) and sampling/importance
resampling (SIR) techniques.21,22 Prior distributions for 24 model
parameters were specified, and 100 000 parameter combinations
were sampled from these distributions.
For each data set, a likelihood function was specified, based on
the assumption that the differences between the model predictions
and the actual observations were normally distributed with zero
mean. The likelihood function for the antenatal clinic data set,
for example, was specified as
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where x(a, t) is the antenatal HIV prevalence measured in year t
in age group a, in a sample of n(a, t) women, and M(a, t) is the
modelled prevalence in pregnant women in year t in age group
a. The likelihood function thus represents the degree of corre-
spondence between the observations and the model predictions.
An aggregate likelihood function was then calculated as
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where Lu is the likelihood function for data source u, and Nu is a
weighting factor applied to data source u. Each Nu weighting
factor was set by trial-and-error, in such a way that the 2.5 and
97.5 percentiles of sampled model outputs (drawn from a set of
10 000 model outputs by using sampling weights proportional to
LuNu) included approximately 95% of the observations in the
relevant data set. Failure to include these Nu weighting factors
would have resulted in prediction intervals that were too
narrow relative to the variation within each data set. The
approach followed in defining the likelihood function and
calculating the Nu weighting factors is described in more detail in
the full report.16
After the aggregate likelihood was defined, it was calculated
for each of the 100 000 parameter combinations. A sample of 500
parameter combinations was then drawn (with replacement)
from the initial set of 100 000 parameter combinations. The
aggregate likelihood values (L) were used as sample weights,
so that the most weight was given to those parameter combina-
tions that produced model results consistent with the empirical
data. The sample of 500 parameter combinations is therefore
one from the posterior distribution of parameter combina-
tions. More detailed model outputs were generated for these
500 parameter combinations, so that average values and 95%
prediction intervals could be calculated for selected model
outputs. The 500 parameter combinations sampled were also
used to determine the posterior distributions for each individual
parameter.
Results
Figure 1 compares the levels of HIV prevalence observed in the
antenatal clinic surveys, x(a, t), with M(a, t), the levels of HIV
prevalence, predicted by the model, in pregnant women
attending public clinics. Almost all of the observed prevalence
levels are contained in the 95% prediction intervals for M(a, t).
The model tends to underestimate recent HIV prevalence rates
in the 25–29 age band, although there is reasonable consistency
between modelled and observed prevalence levels in other age
bands.
Actual numbers of reported deaths were compared with
predicted numbers of reported deaths, for each five-year age
band, each year and each sex (results not shown). The comparison
of actual and modelled deaths in the 20–54 age range is shown in
Fig. 2. In aggregate, the predicted trends in reported mortality
are consistent with the actual numbers of reported deaths in this
age range. Similar comparisons were made with HIV prevalence
levels recorded in the household surveys.
The results of the model are presented in Fig. 3, up to 2005.
Trends in total HIV infections and HIV prevalence are shown in
Fig. 3(a) and (b), respectively. In mid-2005, the average estimated
number of HIV infections in South Africa was 5.1 million, with
a 95% prediction interval of 4.2 million to 6.0 million. This is
equivalent to an HIV prevalence of 11.1% of the total population
(9.1–13.1%). Total HIV infections are still rising in most of the 500
scenarios.
Figures 3(c) and (d) show trends in annual numbers of new
HIV infections and HIV incidence rates, respectively. In most
scenarios, HIV incidence rates peaked during the 1997 to 1999
period, and have been declining since then. The average
estimated number of new HIV infections that occurred between
mid-2004 and mid-2005 is 490 000 (370 000–590 000). The corre-
sponding average estimated HIV incidence rate over the same
period is 1.2% (0.9–1.5%).
The rise in AIDS mortality follows the increase in total HIV
infections [Fig. 3(e)]. Between mid-2004 and mid-2005, the
average estimated number of AIDS deaths was 320 000
(270 000–380 000). This is equivalent to an increase of 7.0 per 1000
(5.8–8.5 per 1000) in the crude mortality rate, as shown in
Fig. 3(f). Associated with the rise in AIDS mortality is an increase
in AIDS morbidity, shown in Fig. 3(g) and (h). The average
estimated number of AIDS cases in South Africa in mid-2005 is
590 000 (500 000–680 000), and the average estimated percentage
of the population sick with AIDS is 1.3% (1.1–1.5%).
Prior and posterior distributions were compared for all 24
parameters. The differences between these distributions were
greatest for the average HIV survival time and the factor by
which the fertility rate is reduced per year of HIV infection in
women who are HIV-positive. These differences are shown in
Fig. 4. The posterior distribution for the average HIV survival
time, in individuals infected at age 29, has a mean of 11.5 years,
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Table 1. Characteristics of data sets used in calibration.
Data set Years Age range Number of records Ref.
HIV prevalence from antenatal clinic (ANC) surveys 1991–2004 15–39 205 865 2
Reported deaths from the Department of Home Affairs (DHA) 1997–2002 20–54 1 099 010 17
HIV prevalence from Nelson Mandela/HSRC household surveys 2002, 2005 15+ 18 112 18, 19
HIV prevalence from RHRU/loveLife household survey 2003 15–24 11 904 20
HSRC = Human Sciences Research Council; RHRU = Reproductive Health Research Unit, University of the Witwatersrand.
with a 95% credibility interval of 10.0–12.9 years. This mean is
greater than that of the prior distribution, 10.5 years (8.6–12.9).
The factor by which fertility is reduced, for each year by which a
woman’s duration of infection increases, has a posterior mean of
0.97 (0.93–1.00), greater than the prior mean of 0.95 (0.88–0.99).
Discussion
This analysis demonstrates that, despite the biases associated
with the HIV prevalence and vital registration data in South
Africa, and the uncertainty regarding the many parameters in
the ASSA2002 model, there is overwhelming evidence that
South Africa is experiencing a severe HIV/AIDS epidemic. With
at least 1000 new HIV infections and at least 700 AIDS deaths
occurring in South Africa every day, there is an urgent need for
concerted action and innovation in HIV prevention and treat-
ment.
An advantage of the approach to uncertainty analysis de-
scribed in this paper is that it is capable of incorporating data
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Fig. 1.Levels of HIV prevalence observed and modelled in pregnant women.Observed values are represented by crosses (), with 95% confidence intervals.Mean of 500
simulated prevalence levels are represented by filled squares (■); 2.5 and 97.5 percentiles of simulated prevalence levels are represented by dashed lines.
Fig. 2. Numbers of reported deaths in the 20–54 age range, predicted and actual. Actual reported numbers are represented by crosses (). Mean of 500 simulated
mortality levels are represented by filled squares (■); 2.5 and 97.5 percentiles of simulated mortality levels are represented by dashed lines.
from multiple sources. Until recently, HIV/AIDS estimates for
countries with generalized epidemics were based almost exclu-
sively on data collected from antenatal clinics, and modelling
approaches to determining prediction intervals usually did not
take into account other empirical data sources.8,9 Increasingly,
however, modellers are having to validate their models against
HIV prevalence data from household surveys23 and mortality
statistics.24 It is therefore important that uncertainty analysis
techniques capable of handling multiple data sources be further
explored. The Bayesian framework is attractive, as it also allows
for prior knowledge of HIV/AIDS epidemiology to be incorpo-
rated into the model.
This analysis suggests that rates of HIV survival in South Africa
are significantly higher than those that have been observed
elsewhere in the developing world,25 a hypothesis supported by
limited survival data in South Africa.26,27 This could be due to the
unique features of HIV-1 subtype C, the dominant HIV-1
subtype in South Africa. Studies have shown that individuals
infected with subtype C develop the synctium-inducing HIV
phenotype less frequently than those infected with other
subtypes, and this phenotype is associated with more rapid
disease progression.28 In addition, comparison of non-synctium-
inducing isolates suggests that subtype C is less fit than subtype
B and other subtypes.29 It has been proposed that the rapid rise in
the incidence of subtype C in recent years may be an indication
that HIV-1 is evolving towards a more attenuated form, with
slower disease progression and thus greater opportunity for
transmission.30 A further possible explanation for the relatively
long HIV survival times in South Africa is better access to pro-
phylaxis against opportunistic infections in the local setting.31
Another finding from this analysis is the small effect of HIV
on fertility in South Africa, relative to that observed in East
Africa.32,33 This is consistent with evidence suggesting that in
African settings with low fertility and high contraceptive use, the
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Fig. 3. Trends in HIV prevalence, HIV incidence, AIDS mortality and AIDS morbidity.Mean of 500 estimates are represented by filled squares (■); 2.5 and 97.5 percentiles
of estimates are represented by dashed lines.
impact of HIV on fertility is small.34,35 Relative to other African
countries, South Africa has low fertility and high levels of contra-
ceptive use.36 A 3% average annual decline in fertility, per year of
HIV infection, therefore seems plausible in the South African
setting.
The only other modelling group that has thus far produced
HIV/AIDS estimates for South Africa together with prediction
intervals is UNAIDS.37 The UNAIDS estimate of total HIV infec-
tions in South Africa in 2005 is 5.5 million (4.9–6.1 million), which
is slightly greater than the estimate of 5.1 million (4.2–6.0 million)
obtained using the ASSA2002 model. However, the UNAIDS
estimate of AIDS deaths in 2005 is very similar to the ASSA2002
estimate of AIDS deaths between mid-2004 and mid-2005, both
estimates being 320 000 with a prediction interval of 270 000 to
380 000. This similarity is surprising, considering the higher HIV
prevalence estimated, and the shorter HIV survival times
assumed, by UNAIDS.38 These differences may be offset by
differences between the two models in the modelling of the
recent antiretroviral rollout.
A disadvantage of the proposed approach to uncertainty
analysis is that the process of setting the weighting factors by
trial-and-error is complex, time-consuming and to some extent
subjective. In addition, the rescaling of the likelihood by these
weighting factors implies that the ‘likelihood function’ is not a
likelihood in the formal statistical sense, but rather a somewhat
arbitrary measure of goodness of fit. Other Bayesian techniques,
such as Bayesian melding,39 could be explored as possible alter-
natives to the GLUE approach employed here. One way in
which Bayesian melding generalizes the standard Bayesian
approach is by allowing for prior distributions on model out-
puts, and this may be an alternative means of representing the
uncertainty around the bias in the data to which the model is
calibrated. In countries in which HIV prevalence data are
collected only from sentinel sites, rather than through nationally
representative surveys, a hierarchical Bayesian approach may
be more appropriate than the one used here.13
This uncertainty analysis considers only parameter uncer-
tainty; uncertainty relating to the model structure is not
reflected. An example of model uncertainty is the ASSA2002
model assumption that, conditional upon age and sex, non-AIDS
mortality and AIDS mortality are independent. If HIV-infected
individuals are more exposed to health risks like smoking and
alcohol than HIV-negative persons,40,41 or are of a lower
socio-economic status than HIV-negative individuals,42–44 the in-
dependence assumption is likely to be invalid and may lead to
some over-estimation of aggregate mortality. Models that relax
the independence assumption could be developed, and tech-
niques such as Bayesian Model Averaging could be used to
extend the analysis to reflect uncertainty regarding the choice of
model.45
This uncertainty analysis was limited to a subset of 24 parameters
in the ASSA2002 model. Further work is required to incorporate
uncertainty regarding mother-to-child transmission of HIV and
paediatric HIV survival, as well as uncertainty regarding demo-
graphic parameters, which may require alternative statistical
techniques.46 Results have been shown only up to 2005, as uncer-
tainty regarding the future impact of antiretroviral treatment
has not yet been incorporated. Projections of uncertainty beyond
2005 will require an assessment of uncertainty relating to
antiretroviral treatment and new prevention strategies such as
male circumcision, microbicides and vaccines.
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ASSA2002 model description and summary of parameters
The ASSA2002 AIDS and Demographic model is a combined
cohort component projection and HIV/AIDS model, developed
by the Actuarial Society of South Africa (ASSA) to describe the
HIV/AIDS epidemic in South Africa. Two modes of HIV trans-
mission are modelled: heterosexual transmission and mother-
to-child transmission. The model contains a large number of
parameters, which can be broadly grouped into the following
classes:
• Demographic parameters
• Sexual behaviour parameters
• Heterosexual HIV transmission parameters
• Adult HIV survival parameters
• Paediatric HIV transmission and survival parameters
• HIV prevention and treatment parameters
• Calibration parameters.
The non-demographic parameters are described in detail else-
where;1 the purpose of this appendix is to provide only an over-
view of the model and its parameters. The uncertainty analysis is
restricted to a subset of the sexual behaviour parameters, hetero-
sexual HIV transmission parameters, adult HIV survival parame-
ters, and calibration parameters. These parameters and the prior
distributions chosen for these parameters are summarized in
Table A1.
Sexual behaviour is modelled by dividing the sexually active
population, between the ages of 14 and 59, into four risk groups.
The ‘PRO’ group consists of sex workers and their regular
clients, while the ‘STD’ group consists of other individuals who
are regularly infected with sexually transmitted diseases (STDs).
Although not regularly infected with STDs, individuals in the
‘RSK’ group are assumed to be at risk of HIV infection. Individ-
uals in the ‘NOT’ group are assumed not to be at risk of HIV
infection, either because they are abstaining from sexual inter-
course or because they are in monogamous long-term relation-
ships with partners who remain faithful to them. Individuals in
the STD group can interact sexually with individuals in the PRO
and RSK groups, but no other interactions between risk groups
are assumed to occur. The ‘sexual mixing’ parameter determines
the extent to which the STD group interacts with the PRO and
RSK groups, and can take on any value between 0 and 1 (0 imply-
ing no mixing between risk groups, and 1 implying random
mixing2). Different annual numbers of partners and frequencies
of sex are assumed for each risk group. A two-parameter function
is used to determine the ‘sex activity curve’ for women, which is
a measure of the relative frequency of sex and the relative rate of
partner change at different ages. The two parameters in this
function determine the earliest age at which sexual activity
begins (the ‘position factor’) and the amount of sex at young ages
relative to older ages (the ‘shape factor’). Most sexual behaviour
parameters are specified for females, and male parameters are
calculated to be consistent with these.
Adults infected with HIV are assumed to progress through
four stages of disease before dying from AIDS, in the absence of
antiretroviral treatment. These four stages correspond to the
four stages of the WHO Clinical Staging System,3 with the first
two stages representing asymptomatic infection, the third stage
representing pre-AIDS symptoms, and the fourth stage repre-
senting AIDS. The time spent in each stage of disease is assumed
to follow a Weibull distribution, and the Weibull shape parameters
of these distributions are assumed to be linearly related to the
Weibull means, with a ‘gradient parameter’ determining the
slope of this linear relationship. For a specified mean survival
Table A1. Prior distributions for the 24 parameters included in the uncertainty analysis.
Parameter Prior distribution Prior (mean, 95% interval)
Sexual behaviour parameters
% of initial population in STD risk group Beta (19.8, 79.2) 20% (13–28%)
% of initial population in RSK risk group Beta (19.0, 63.7) 23% (15–33%)
Annual average number of partners (female PRO) Gamma (25, 10) 250 (162–357)
Annual average number of partners (female STD) Gamma (25, 0.48) 12.0 (7.8–17.1)
Annual average number of partners (female RSK) Gamma (25, 0.04) 1.00 (0.65–1.43)
Sexual mixing parameter Beta (12, 12) 0.50 (0.31–0.69)
Shape factor (of sex activity curve) Beta (24.9, 4949) 0.0050 (0.0032–0.0071)
Coital reduction factor (K) Uniform (0, 1) 0.50 (0.025–0.975)
% reduction in annual number of partners due to social marketing programmes Beta (0.8, 7.2) 10.0% (0.1–36.7%)
Heterosexual HIV transmission parameters
Probability of HIV transmission per act of sex
Male to female (both partners in RSK group) Beta (24.95, 12449) 2.0 (1.3–2.9) per 1000
Female to male (both partners in RSK group) Beta (24.97, 24949) 1.0 (0.6–1.4) per 1000
Male to female (partners in STD/PRO groups) Beta (24.82, 3521) 7.0 (4.5–10.0) per 1000
Female to male (partners in STD/PRO groups) Beta (24.87, 4949) 5.0 (3.2–7.1) per 1000
Increase in infectiousness per log increase in HIV viral load Gamma (6.25, 0.28) 175% (66–337%)
Increase in susceptibility per year below age 25 Gamma (16, 0.0075) 12.0% (6.9–18.6%)
Adult HIV survival parameters
Mean HIV survival time (for individual infected at age 29), in years Gamma (110, 0.095) 10.5 (8.6–12.5)
Decrease in mean survival time per 10-year increase in age at HIV acquisition, in years Gamma (25, 0.06) 1.50 (0.97–2.14)
Gradient parameter Gamma (4, 0.075) 0.30 (0.08–0.66)
Calibration parameters
% of adult deaths reported in 1999 Beta (179.8, 34.2) 84% (79–89%)
Ratio of antenatal HIV prevalence in all public clinics to that in sampled clinics, in 1990 Beta (19.2, 4.8) 0.80 (0.62–0.93)
Odds ratio for HIV in women attending private clinics (controlling for age and race) Beta (5.83, 2.50) 0.70 (0.37–0.94)
Axsym false positive rate Exponential (50) 2.0% (0.0–7.4%)
Orasure false positive rate Exponential (50) 2.0% (0.0–7.4%)
Factor by which fertility reduces per year of HIV infection Beta (49.19, 2.59) 0.95 (0.88–0.99)
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time, the gradient parameter determines the variance of the
survival time; an increase in the gradient parameter implies a re-
duction in the variance. The mean HIV survival time is assumed
to depend on the age at which individuals become HIV-infected,
with individuals infected at older ages progressing to death
more rapidly than those infected at young ages.4
The probability of heterosexual transmission of HIV, per act of
sex with an infected partner, is assumed to depend on several
factors. The most important of these are the sex of the susceptible
partner and the risk groups of the susceptible and infected
partners. It is also assumed that the disease stage of the infected
partner affects the probability of HIV transmission. The levels of
infectiousness in the different stages are estimated by assuming
average levels of HIV viral load in each disease stage,5,6 as well as
a factor by which the probability of HIV transmission increases
per log increase in viral load.7,8 It is also assumed that in young
women, age affects HIV susceptibility, with susceptibility increas-
ing by a particular factor for each year below the age of 25.9,10
Four HIV prevention programmes are allowed for in the
model: social marketing, syndromic management of STDs,
voluntary counselling and testing (VCT), and prevention of
mother-to-child transmission (PMTCT). These interventions are
assumed to be introduced at rates consistent with public health
sector statistics.11–13 Social marketing programmes are assumed to
lead to increases in condom usage and reductions in average an-
nual numbers of partners.
The effects of highly active antiretroviral treatment (HAART)
are modelled by adding two stages to the basic four-stage model
of adult HIV survival: one representing people receiving HAART
and the other representing people who have discontinued treat-
ment. Treatment is assumed to be started at the time of the first
AIDS-defining illness, and assumptions about proportions of
individuals starting HAART have been set to be consistent
with reported numbers of individuals receiving HAART.14 The
Table A2. Parameters not included in the uncertainty analysis.
Demographic parameters
• Initial population size and initial age- and sex-distribution of the population (in the year in which the epidemic starts)
• Non-AIDS mortality rates (by age, sex and year)
• Net migrants into South Africa (by age, sex and year)
• Fertility rates (by age and year)
• Proportion of births that are male
Sexual behaviour parameters
• % of sexually active individuals initially in the ‘PRO’ group
• Number of HIV-infected individuals temporarily entering the PRO group per annum, from outside South Africa
• Proportion of migrants to/from South Africa in each risk group
• Year in which HIV-infected migrants first enter South Africa (‘start year’)
• Rates at which youth become sexually experienced
• Correlation between age at sexual debut and propensity for sexual risk behaviour
• Coital frequencies within partnerships (by risk group of both partners)
• Rates of condom use (by age and risk group)
• ‘Position factor’ for sex activity curve
• Age of partner preferences
Heterosexual HIV transmission parameters
• Average level of HIV viral load in each disease stage
• Condom effectiveness
Adult HIV survival parameters
• % of adult HIV survival time spent in each disease stage
Paediatric HIV transmission and survival parameters
• Rates of mother-to-child transmission (before or at birth and through breastfeeding)
• Rates of HIV survival and rates of progression to AIDS in children infected at or before birth
• Rates of HIV survival and rates of progression to AIDS in children infected through breastfeeding
HIV prevention and treatment parameters
• Extent to which social marketing programmes have been phased in
• Extent of improvement in condom usage due to social marketing programmes
• Phase-in of syndromic management of STDs and effectiveness in reducing HIV transmission
• Phase-in of VCT and effectiveness in increasing condom use and reducing coital frequencies (by HIV stage)
• Phase-in and effectiveness of PMTCT
• Phase-in of HAART and levels of mortality and morbidity after starting HAART
• Change in sexual behaviour after starting HAART
• Effect of HAART on VCT uptake and condom use in general population
• Log reduction in HIV viral load after starting HAART
Calibration parameters
• % increase in proportion of deaths that are reported, per annum
• Sensitivity of HIV antibody tests
• Correlation between HIV risk behaviour and pregnancy at young ages
• % of women attending private health facilities (by age and race)
frequency of sex in the different stages of disease is assumed to
depend on both the proportion of adults who know their HIV
status and the severity of symptoms in the different disease
stages.15–18 Symptoms are assumed to be most severe in individu-
als who have untreated AIDS and individuals who have discon-
tinued HAART. Beta priors are used to represent the extent of
uncertainty surrounding the reduction in coital frequencies due
to HIV symptoms in each stage, but to ensure that the reductions
in the different stages vary proportionally to one another across
the different simulations, the same coital reduction factor, K, is
used to sample from each of these beta distributions.
For the purpose of calibrating the model to HIV prevalence
data and vital registration data, it is necessary to take into account
various sources of bias associated with these data. In the case of
the vital registration data, comparison of the modelled and
actual deaths is only valid if the modelled deaths are adjusted to
make some allowance for incompleteness of the reporting of
deaths.19 In the case of HIV prevalence data, it is necessary to
allow for possible false positive reactions produced by the HIV
tests used,20–22 if there is no confirmatory testing of positive test
results. The blood test used in the antenatal survey (the Abbott
Axsym ELISA) differs from the saliva test used in the 2002 HSRC
and 2003 RHRU surveys, which is based on the Orasure collec-
tion device. Separate priors have therefore been specified for the
false positive rates on these two tests. Antenatal survey data are
also biased due to the effect of HIV on fertility,23 and the model
therefore assumes that fertility in HIV-infected women reduces
exponentially, relative to that in HIV-negative women, the
longer they have been infected with HIV.
In the case of the antenatal clinic survey data, it is also neces-
sary to allow for two sources of sampling bias: bias towards
urban antenatal clinics in the early years of the survey, and the
effect of not including women seeking antenatal care in private
health facilities. The former source of bias is significant because
HIV prevalence is substantially higher in urban areas than in
rural areas, particularly in the early stages of an HIV/AIDS
epidemic. It is therefore assumed that the ratio of antenatal prev-
alence in all public clinics to that in sampled clinics, in 1990, is less
than one, and that this ratio increases linearly to one in 1999, by
which time a new survey protocol had been introduced to
remove the urban bias.24 The effect of not including women
attending private antenatal clinics can be estimated if assump-
tions are made about the proportion of pregnant women attend-
ing private clinics in each age and race group, and the
independent effects of race and private clinic attendance on a
woman’s odds of HIV infection. As the latter effect is difficult to
estimate reliably, it has been included in the uncertainty analysis.
The prior distributions for the 24 parameters included in the
uncertainty analysis are summarized in Table A1. In general,
beta priors are used for those parameters restricted to the range
[0, 1] and gamma priors are used for those parameters restricted
to the range [0, ∞). Exponential priors are used for the false posi-
tive rates, as the exponential distribution matches the strongly
skewed distribution of false positive results more closely than
the beta distribution. Values are sampled from the different prior
distributions independently of one another, so that there is no
dependency between the prior distributions.
A large number of ASSA2002 parameters have not been
included in this uncertainty analysis. In most cases, the excluded
parameters are omitted because they are believed to have little
effect on the correspondence between model outputs and
observed levels of HIV prevalence and mortality, or because the
empirical evidence used to determine the parameters is suffi-
ciently reliable to warrant treating the parameters as known. As
this analysis considers uncertainty only in projections up to
2005, parameters that are only of significance beyond this date
(e.g. HAART rollout and effectiveness) are also excluded from
the analysis. The parameters that have not been included in the
uncertainty analysis are summarized in Table A2.
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